心脏手术中常规吸入米力农与伊洛前列素减少正性肌力药使用
该回顾性队列试点研究纳入在澳大利亚皇家墨尔本医院由同一外科医生和麻醉团队连续进行心脏手术的患者,比较常规实施吸入肺血管扩张剂(米力农4 mg与伊洛前列素20 µg)前后14个月的情况。
要点
- 常规吸入米力农4 mg与伊洛前列素20 µg可减少心脏手术后正性肌力药使用。
- 吸入组围术期正性肌力药使用率62.5% vs 86.8%,OR 0.253(95%CI 0.083-0.764)。
核心结论
- 在体外循环(CPB)前后常规吸入米力农4 mg与伊洛前列素20 µg,与心脏手术后正性肌力药使用减少相关。
研究设计与样本
- 回顾性队列试点研究,纳入同一外科医生和麻醉团队在常规实施吸入肺血管扩张剂(2017年8月)前后14个月内连续进行心脏手术的患者。
- 米力农4 mg与伊洛前列素20 µg在CPB开始前和关胸时通过振动网孔雾化器(Aerogen)吸入。
- 两名相互盲法的研究者从电子和书面医疗记录中提取数据;主要结局为围术期任何正性肌力药使用,采用Fisher精确检验分析组间差异。
主要发现
- 两组主要术后并发症或费用无显著差异。
临床怎么用
- 对于心脏手术患者,可考虑在CPB开始前和关胸时经振动网孔雾化器吸入米力农4 mg与伊洛前列素20 µg,以减少围术期正性肌力药使用。
- 该干预可能有助于缩短ICU停留时间,且未增加主要术后并发症或费用。
局限性
- 本研究为回顾性队列试点研究,样本量有限,结论需进一步验证。
- 研究由单一外科医生和麻醉团队完成,结果外推性可能受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Catecholamine inotropes are frequently used after cardiopulmonary bypass (CPB) but may have undesirable effects. The aim was to identify whether the routine use of inhaled pulmonary vasodilators might reduce the requirement for inotrope drugs after cardiac surgery. METHODS: Retrospective cohort study of sequential patients undergoing cardiac surgery at the Royal Melbourne Hospital performed by a single surgeon and anesthesia care team, within 14 months before and after routine implementation of inhaled pulmonary vasodilators, August 2017. Milrinone 4 mg and iloprost 20 µg were inhaled using a vibrating mesh nebulizer (Aerogen) before initiation of CPB and at chest closure. Other aspects of clinical management were unaltered over the time period. Two investigators blinded to each other extracted data from electronic and written medical records. The primary outcome was any use of inotropes in the perioperative period; a Fisher exact test was used to analyze any differences between the 2 groups. Demographic data, hemodynamic data, and use of inotropes and vasopressors were collected from induction of anesthesia to 36 hours postoperative in the intensive care unit (ICU). Hospital and ICU length of stay, cost, and complications were collected. RESULTS: Any use of inotropes was significantly lower with inhaled pulmonary dilators (62.5% vs 86.8%, odds ratio [95% confidence interval {CI}], 0.253 (0.083-0.764); P = .011), including intraoperative inotrope use (37.5% vs 86.8%, odds ratio [95% CI], 0.091 (0.03-0.275); P < .001). ICU length of stay was significantly lower with inhaled pulmonary dilators (45 hours, interquartile range [IQR], 27-65 vs 50 hours, IQR, 45-74; P = .026). There were no significant differences among major postoperative complications or costs between groups. CONCLUSIONS: Routine use of inhaled milrinone 4 mg and iloprost 20 µg before and after CPB is associated with reduced postoperative inotrope use.
引用
- Hu X, Li X, Boggett S, et al. Routine Intraoperative Inhaled Milrinone and Iloprost Reduces Inotrope Use in Patients Undergoing Cardiac Surgery: A Retrospective Cohort Pilot Study. Anesth Analg. 2020. PMID: 32371741. doi:10.1213/ANE.0000000000004793
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。